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Objective. To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric
fever. Design. A randomized, open-label, active control trial with two parallel arms. Setting. Emergency Room and Outpatient
Clinics in Patan Hospital, Lagankhel, Lalitpur, Nepal. Participants. Patients with clinically diagnosed uncomplicated enteric
fever meeting the inclusion criteria. Interventions. Patients were allocated to receive one of two drugs, Gatifloxacin or
Cefixime. The dosages used were Gatifloxacin 10 mg/kg, given once daily for 7 days, or Cefixime 20 mg/kg/day given in two
divided doses for 7 days. Outcome Measures. The primary outcome measure was fever clearance time. The secondary
outcome measure was overall treatment failure (acute treatment failure and relapse). Results. Randomization was carried out
in 390 patients before enrollment was suspended on the advice of the independent data safety monitoring board due to
significant differences in both primary and secondary outcome measures in the two arms and the attainment of a priori
defined endpoints. Median (95% confidence interval) fever clearance times were 92 hours (84–114 hours) for gatifloxacin
recipients and 138 hours (105–164 hours) for cefixime-treated patients (Hazard Ratio[95%CI]=2.171 [1.545–3.051], p,0.0001).
19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out
of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI]=0.031 [0.004 – 0.237], p,0.001). Overall treatment failure
patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95%
confidence interval) 37.6 % (27.14%–50.2%) in the cefixime group and 3.5% (2.2%–11.5%) in the gatifloxacin group
(HR[95%CI]=0.084 [0.025–0.280], p,0.0001). There was one death in the cefixime group. Conclusions. Based on this study,
gatifloxacin is a better treatment for uncomplicated enteric fever as compared to cefixime. Trial Registration. Current
Controlled Trials ISRCTN75784880
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INTRODUCTION
Enteric fever (Typhoid and Paratyphoid fever) is a systemic
infection caused by the bacterium Salmonella enterica serovar Typhi
(S.typhi) or Salmonella enterica serovar Paratyphi (S. paratyphi)
which in humans is transmitted through the fecal-oral route [1,2].
Today the vast burden of disease is encountered in the developing
world where sanitary conditions remain poor. The best global
estimates are of at least 22 million cases of typhoid fever each year
with 200,000 deaths [3]. Crucially these are almost exclusively
confined to resource poor countries. A recent Cochrane review [4]
on typhoid treatments underscored the need for large sample size
drug interventional trials, especially in children in whom this
disease predominates.
In 1948 the introduction of chloramphenicol revolutionized the
treatment of typhoid fever [5,6]. Unfortunately the emergence of
resistance to the ‘‘first line’’ antimicrobials (for example, cipro-
floxacin) has been a major setback and has given rise to the
possibility of untreatable enteric fever [7,8]. Gatifloxacin,
a relatively inexpensive fluoroquinolone antibiotic in South Asia
with once daily oral administration, is a new broad spectrum
synthetic 8-methoxyfluoroquinolone which has the lowest mini-
mum inhibitory concentration (MIC) against S. typhi from Nepal
[9]. This in vitro activity needs to be verified clinically before
gatifloxacin can be recommended for widespread use. Cefixime,
an orally administered third generation cephalosporin, is a com-
monly used drug in South Asia for the treatment of enteric fever.
Although cefixime is recommended as a drug of choice by the
World Health Organization (WHO) for the treatment of resistant
typhoid fever [10] it is relatively expensive in South Asia and has
to be administered for a longer duration than the currently used
fluoroquinolones. Clearly there is an urgent need for a treatment
[11] that combines ease of oral administration, with speed of
clinical response, reduction in secondary transmission and in-
expensiveness. In this open randomized trial, we aimed to
compare clinical outcomes for the treatment of uncomplicated
enteric fever with gatifloxacin or cefixime in an outpatient setting.
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Participants
The study was approved by Nepal Health Research Council and
Oxford Tropical Research Ethics Committee. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1. We
enrolled patients who presented to the outpatient or emergency
department of Patan Hospital, Lalitpur, Nepal from June 5, 2005
to September 8, 2005. Patan Hospital is a 318 –bed hospital
located in the Lalitpur district in Kathmandu Valley. Patients were
eligible to enter the study if they had clinically diagnosed enteric
fever and their residence was within approximately 2.5 km radius
from the hospital. Other inclusion criteria were that patients must
be aged between 2 and 65 years, able to take oral medications,
non-pregnant and non-lactating, without a history of seizures, able
to stay in the city for the duration of the treatment, not known to
have contraindications to either cephalosporins or fluoroquino-
lones and willing to give informed written consent to take part in
the study. For children enrolled into the study, written informed
consent was taken from a parent. Patients were excluded from the
study if they had any signs of complicated typhoid defined as the
presence of jaundice, gastrointestinal bleeding, peritonism, shock,
encephalopathy, convulsions, myocarditis or arrythmia at the time
of enrollment. Patients who had received a third generation
cephalosporin, fluoroquinolone or macrolide in the week prior to
presentation to our clinic were also excluded.
Interventions
On presentation to Patan Hospital all patients with fever without
an obvious focus were referred to the enteric fever study clinic,
where they were seen by the study physician. Patients who fulfilled
the inclusion criteria were randomly assigned to receive Gati-
floxacin (Broadband
TM, Novartis AG Basel, Switzerland) 10 mg/
kg/day [12], in a single dose orally for 7 days or Cefixime
(Cifex
TM, Aegis, Nicosia, Cyprus) 20 mg/kg/day [13] in two
divided doses orally for 7 days. Both drugs were administered in
tablet form, cut and weighed in a sensitive scale to ensure that
underdosing did not occur. To children who were apprehensive of
swallowing the tablet, the drug was embedded in a banana and
given. All patients were asked to swallow the study drug under
direct observation during each visit.
Each patient had haematocrit, total leucocyte count with
differential, serum creatinine, total bilirubin, alanine aminotran-
ferase(ALT), and aspartate aminotransferase(AST) measured, and
blood and stool cultures were also performed before the start of the
study intervention.
The exact location of the patient’s home was recorded and the
first dose of drug administered at the clinic. We employed six
Community Medical Auxiliaries (CMA) who had all received at
least 15 months of prior formal primary health care worker
training and been registered in a government recognized in-
stitution. The CMAs visited patients twice daily at their homes to
perform a simple clinical assessment, measure the oral tempera-
ture and give directly observed therapy with the study drugs. The
CMA visited the patient’s home every 12 hours, morning and
evening, until day 10 following enrollment or complete resolution
of illness, whichever came later. The oral temperature of the
patient was recorded twice every day by the CMA and a note was
made of the timing and dosages of acetaminophen intake. The
quality of patient-visits was ensured by regular unplanned
supervisory checks in which the study doctor accompanied the
CMA during the visits to patients’ homes
CMAs were asked to send patients immediately to the hospital
on encountering any severe symptoms, and the patients also were
asked to attend clinic if they had any severe symptoms at any other
time. A symptom questionnaire was used daily during each visit to
monitor any adverse events. Any patient with any severe symptom
was seen by the study physician. The CMAs and study physicians
held daily case conferences at which all the study patients were
discussed.
All patients regardless of the culture results were seen at hospital
on Day 10 following enrollment. Blood and stool cultures were
repeated on Day 10 in all culture positive patients and thereafter if
the patient again became ill with probable enteric fever. All culture
positive patients were followed up until six months after
enrollment, and stool cultures were performed at the end of the
first, third and sixth month.
Microbiological Procedures Blood culture was performed
on media containing tryptone soya broth and sodium polyethanol
sulphonate, incubated at 37 C and examined daily for growth over
7 days [11]. Salmonella enterica serotype Typhi or Paratyphi A, B or
C isolated in culture were identified using standard biochemical
tests and specific antisera (Murex Biotech, Dartford, England).
Antibiotic susceptibilities were determined during isolation using
the Kirby-Bauer disc diffusion method involving antibiotic discs
containing Nalidixic acid, Ofloxacin, Ciprofloxacin, Chloramphe-
nicol, Ampicillin, Cotrimoxazole, Cefixime and Cefotaxime
(HiMedia Laboratories, Mumbai, India). Minimum Inhibitory
Concentrations (MICs) were determined later for organisms stored
in glycerol (bacterial preserver) at -70C. The MICs were
determined by Chloramphenicol, Nalidixic acid, Gatifloxacin,
Cefixime, Ceftriaxone and Gemifloxacin E-tests
TM (AB Biodisk,
Solna, Sweden), according to the manufacturer’s instructions. The
sensitivity tests were interpreted using Clinical and Laboratory
Standards Institute criteria for Enterobacteriaceae.
Objectives
The objective of the study was to compare the efficacy of
Gatifloxacin and Cefixime in the treatment of uncomplicated
culture positive enteric fever.
Outcomes
The primary outcome was the fever clearance time (FCT). FCT
was defined as time to first drop in oral temperature # 37.5uC,
remaining # 37.5uC for 48 hours. The secondary outcomes
included acute treatment failure. Acute treatment failure was
defined as including any severe complication; the persistence of
fever (. 38 C); the persistence of symptoms for more than
7 days after the start of treatment , requiring additional or
rescue treatment. If a patient had a temperature above 37.5 and
below 38 for more than 7 days, but did not need additional or
rescue therapy, and subsequently their fever cleared by day 10,
that patient would not qualify as an acute treatment failure.
Patients who failed the study treatment were given rescue
treatment.
The rescue drug was Ofloxacin 20 mg/kg/day orally in two
divided doses for 14 days for the Cefixime group, and Ceftriaxone
40 mg/kg/day IV in a single daily dose for 14 days for the
Gatifloxacin group. For the Cefixime group alone, if on day 8 of
treatment the patient still had a fever of .=38uC, the study drug
was continued for 10 days and the patient categorized as acute
treatment failure. If the temperature on Day 10 was .37.5, rescue
treatment was given.
A relapse was defined as fever with a positive blood culture
within a month of completing treatment. All the relapses were
Typhoid Treatment Trial
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patient given rescue treatment or prolonged treatment was
precluded from the ‘‘relapse’’ group.
Patients categorized as ‘‘overall treatment failures’’ included
patients experiencing acute treatment failure, plus those falling
into the relapsed category, plus all deaths within the trial follow up
period.
Sample size
The sample size was calculated to detect a FCT difference of
approximately 48 hours between gatifloxacin (assumed median
FCT 156 hrs) and cefixime (assumed median FCT 204 hrs) [14]
with p=0.05 and power=80%. The accrual time for recruitment
was assumed to last 70 days, and that the last patient would be
followed up until 8 days after recruitment. Therefore, we
estimated the minimum sample size at 235 participants. Assuming
a loss to follow-up of 5%, the sample size was calculated as 125
blood culture positive patients in each arm.
Before the recommended sample size had been reached, once
169 blood culture positive patients had been enrolled, the
independent data safety monitoring committee (DSMC) advised
the Principal Investigators to stop recruitment to the trial based on
a priori defined difference (p,0.01) between the two treatment
arms in the primary endpoints of the study.
Randomization—Sequence generation
Patients were randomized in blocks of 100 from a computer
generated randomization list, by an investigator not involved in
patient recruitment or assessment.
Randomization—Allocation concealment
The randomization sequence and block size was concealed from
the physicians allocating treatment and managing the patients,
prior to patient enrollment. Treatment allocations were kept in
sealed opaque envelopes, which were opened only on enrollment
of the patient to the study after all inclusion and exclusion criteria
had been checked.
Randomization—Implementation
Participants were enrolled by the study physician in the same
order in which they presented to the study clinic. The sealed
envelopes were opened in strict numeric sequence.
Blinding
Blinding was not feasible in this trial due to logistical reasons.
Statistical methods
All data were entered into an electronic database (Microsoft
Office Access Version 2003, Wash., USA), and analyses was
performed using Stata 9 (Stats Corp LP; Texas, USA). ).
Continuous covariates were compared between groups of patients
using the Mann-Whitney test, and categorical covariates were
compared using the chi-square test or Fisher’s exact test when
appropriate. Fever clearance times and time to relapse were
analyzed using Kaplan Meier survival curves and compared
between the two groups using the logrank test. Binary outcomes
(clinical failures) were compared between the two treatment
groups using Fisher’s exact test. Analysis was done in all
randomized patients (intention to treat, ITT) and separately in
patients with positive pretreatment culture (per protocol, PP) and
negative pretreatment culture.
RESULTS
Participant flow
Of the 482 patients from the study area who were clinically
diagnosed with enteric fever, 390 patients were enrolled into the
study and randomized. 92 patients were ineligible, the main
reason (49 patients) being a history of already having taken
antibiotics (fluoroquinolone, macrolide, or third generation
cephalosporin) within one week prior to study entry (Figure 1).
Among all randomized patients, 187 patients were assigned to
receive cefixime and 203 to gatifloxacin. 77 patients assigned to
receive cefixime were blood culture positive for enteric fever whilst
92 of those assigned to receive gatifloxacin were culture positive
.There were unequal number of positive patients in each of the study
arms. One possible reason for the difference in number of culture
positive patients between study arms is that cultures were drawn and
culture results obtained after randomization had been done.
Recruitment
We enrolled patients who presented to the outpatient or
emergency department of Patan Hospital, Lalitpur, Nepal from
June 5, 2005 to September 8, 2005. All enrolled patients were
followed up for at least 10 days after recruitment. Patients with
a positive pretreatment blood culture were followed up for
6 months after enrollment.
At the point that the DSMC asked to examine the trial data for
the primary outcome measure in positive pre-treatment patients,
the median fever clearance time was 92 hours (95% CI, 84–
114 hours) for the gatifloxacin treated patients and 138 hours (95%
CI, 105–164 hours) for cefixime treated patients. The difference
between the two treatment arms was 46 hours (p,0.0001).
Baseline data
Admission characteristics are shown for all ITT patients (Table 1)
and for all PP patients (Table 2). The median age of patients
enrolled into the trial was 17 with a range of 2–64 years. There
were no baseline differences in the culture positive and culture
negative groups, other than temperature at presentation, AST and
ALT which were higher and platelets and total WBC which were
lower in the culture positive patients as compared to the culture-
negative patients. Among all PP patients, there were no differences
in the baseline characteristics between the two treatment groups.
There were 40 patients, 15 in the gatifloxacin arm and 25 in the
cefixime arm, who had taken amoxycillin up to the week before
study entry. Of these 4 and 7 were culture-positive respectively.
Numbers analyzed
Analysis was done in all 390 randomised patients (ITT) and
separately in 169 patients with positive pre-treatment culture (PP).
All endpoints were analysed in the ITT and PP populations, apart
from relapse which was only analysed in the PP population.
Outcomes and estimation
Primary outcome In all ITT patients, median (95% confidence
interval) fever clearance time was 102 (90–117) hours for the
cefixime group and 72 (62–80) hours for the gatifloxacin group,
logrank test p,0.0001, Hazard Ratio[95%Confidence Interval]=
1.821 [1.466–2.263]. The proportion of all patients failing through
time to clear fever is shown in Figure 2. At day 7 fever clearance
rate was 73.9% (67.0% – 80.3 %) in cefixime group and 94.2%
(90.2% – 96.9%) in gatifloxacin group.
In the PP group, median (95% CI) fever clearance time was
92 hours (84–114 hours) for gatifloxacin recipients and 138 hours
Typhoid Treatment Trial
PLoS ONE | www.plosone.org 3 June 2007 | Issue 6 | e542(105–164 hours) for cefixime-treated patients (HR[95%CI]=
2.171 [1.545–3.051], p,0.0001). The proportion failing to clear
fever for each study drug through time after treatment is shown
(Figure 3). At day 7 the fever clearance rate was 62.7% (95 %
CI=51.5%–73.8%) in the cefixime group and 91.8% (95 %
CI=84.8%–96.4%) in the gatifloxacin group.
In the group with negative blood culture but clinically diag-
nosed enteric fever (Fig 1), the FCT was 82 hours (95% CI=44–
94 hours) for the cefixime group and 39 hours (95%CI=28–
54 hours) for the gatifloxacin group (HR[95%CI]=1.740 [1.309–
2.312], p,0.0001 logrank test).
Secondary Outcomes In the ITT group, overall, 30 out of
167 (18%) in the cefixime group and 2 out of 190 (1%) in the
gatifloxacin group were acute clinical failures, OR[95%CI]=
0.049 [0.011–0.207], p,0.001, Fisher’s exact test.
InthePPgroup,19 out of 70(27%) patients whocompleted the7-
day trial had acute clinical failure in the cefixime recipients as
compared to 1 out of 88 (1%) in the gatifloxacin recipients (Odds
Ratio [95%CI]=0.031 [0.004 – 0.237], p,0.001). Considering all
patients to be failures who dropped out of the study before
completion of the seven day treatment course, 26 out of 77 (34%)
failed in the cefixime group as compared to 5 out of 92 (5%) in the
gatifloxacin group (OR[95%CI]=0.112 [0.041 – 0.312], p,0.001).
138 patients were evaluable for relapse; 20 had acute treatment
failure and 11 withdrew from the study before day 7. In total, eight
relapses (Figure 1) were observed. Relapse rates were 12.4% (6/51)
in the cefixime group and 3.4% (2/87) in gatifloxacin group
(HR[95%CI]=0.185 [0.037–0.915], p= 0.0199). The Kaplan-
Meier plots for the time of relapse are shown in Figure 4.
Overall failures (acute treatment failure plus relapse plus death)
were 29 in number (Figure 1). Overall failure rate at 1 month was
estimated as 37.6% (95% CI=27.14% – 50.2%) in the cefixime
group and 3.5% ( 95% CI =2.2%–11.5%) in the Gatifloxacin
group (HR[95%CI]=0.084[ 0.025–0.280], p,0.0001) ( Figure 5).
From patients with negative cultures, 11 had acute clinical
failures, 10 (out of 97, 10%) in Cefixime group and 1 (out of 103,
1%) in the Gatifloxacin group, OR[95%CI]=0.086 [0.011–
0.686], p=0.004, Fisher’s exact test.
Similarly, treating drop-out as treatment failures, we had 50 out
of 187 (27%) in the Cefixime group and 15 out of 203 (7%) in the
Gatifloxacin group acute treatment failures, OR[95%CI]=0.219
[0.118–0.405], p,0.001, Fisher’s exact test.
Figure 1. Profile of the Trial. The consort flow diagram showing the flow of participants through the trial.
doi:10.1371/journal.pone.0000542.g001
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Among all culture positive patients in the cefixime group, one
patient (1/70, 1%) had S. Paratyphi A cultured from her blood on
day 10,but there were no (0/88, 0%) positive blood culture
growths in the gatifloxacin group on day 10.
No patient was found to be a persistent carrier of S. Typhi or
Paratyphi A in their stool. A positive stool culture for S. Typhi was
seen for one patient on day 10 and for another on day 30.
Subsequent cultures were negative for both patients. We were able
to obtain stool cultures from 147 (87%), 141 (83%), and 130 (77%)
pretreatment blood culture positive patients at one, three, and six
months respectively.
Microbiology Antibiotic sensitivity testing revealed that all
strains were sensitive to gatifloxacin, cefixime, ceftriaxone or
gemifloxacin. One strain was resistant to chloramphenicol, and
136 (83%) of the pretreatment isolates were nalidixic acid resistant
strains (NARST). Minimum inhibitory concentration (MIC) was
determined for 161 of the pretreatment blood culture isolates. The
median (range) MICs for each antibiotic were as follows: gatiflox-
acin 0.125 (0.006–0.5) mg/mL, cefixime 0.380 (0.016–2.0) mg/mL,
nalidixic acid .256 (1.5-.256) mg/mL, chloramphenicol 8.0 (1.5-
.256) mg/mL, ceftriaxone 0.125 (0.047–0.5) mg/mL and
gemifloxacin 0.125 (0.004–0.5) mg/mL.
Adverse events
Among all patients who received cefixime, there was one death,
which might have been due to the development of disease-related
complications during treatment. This patient was enrolled on the
fourteenth day of his illness. On day 6 of treatment the patient
complained of reddish stool and petechiae and was immediately
admitted to hospital where he developed severe thrombocytopenia
and gastrointestinal bleeding. He developed acute respiratory
distress syndrome and was mechanically ventilated. He developed
disseminated intravascular coagulation and succumbed to his
illness on day 21 of entry into the trial. His pretreatment blood
culture grew S. Paratyphi A which was sensitive to cefixime with
an MIC of 0.38 mg/mL. One patient developed erythematous skin
rash which needed two doses of oral antihistamine.
Among all patients who received gatifloxacin there were 2
patients with excessive vomiting, which required intravenous
antiemetics and fluids and observation in the hospital emergency
room for upto 6 hours. There were an additional 23 patients who
complained of excessive nausea and occasional vomiting after
ingestion of the drug. Of these, two needed oral antiemetics; in the
remaining 21 patients no intervention was required.
DISCUSSION
Interpretation
In this study examining fever clearance time, acute treatment
failure and relapse as indicators of treatment efficacy, that the
results raise doubts on the usefulness of cefixime and suggest that
gatifloxacin is a potent choice for the treatment of uncomplicated
enteric fever.
Febrile illness is one of the most common reasons for
presentation to hospitals in many developing countries. In patients
with fever, a very common clinical diagnosis is enteric fever, and S.
Table 1. Baseline characteristics all patients.
..................................................................................................................................................
PATIENT CHARACTERISTICS Culture negative (213) Culture positive (169)
No of males/No of females 136/77 111/58
Age (yrs) 18 (2–64) 17 (2.75–50)
Number Aged ,14 years (%) 79(37.1) 60 (35.5)
Weight (Kg) 44 (10–80) 46 (10–73)
Duration of fever before treatment (days) 5 (0–21) 5 (2–23)
Median oral temperature at presentation(95% CI, range) (in degrees C) 38.7 (38.6–39; 36.5–40.7) 39(38.8–39.2; 36.8–41)
Headache, Number with (%) (median duration [days]) 204 (95.7) (4) 164 (97.0) (5.)
Anorexia, Number with (%) (median duration [days]) 160 (75.1) [4] 129 (76.3) [4]
Abdominal Pain, Number with (%) (median duration [days]) 88 (41.3) [4] 80 (47.3) [4]
Cough, Number with (%) (median duration [days]) 83 (39.0) [3] 59 (34.9) [3]
Diarrhoea, Number with (%) (median duration [days]) 45 (21.1) [3] 41 (24.3) [3]
Vomiting, Number with (%) (median duration [days]) 30 (14.1)[1] 27 (16.0) [2]
Abdominal tenderness ( n [%]) ) 32 [15.1] 23 [13.6]
Splenomegaly ( n [%]) 18 [8.5] 18 [10.6]
Hepatomegaly ( n [%]) 12 [5.76] 9[5.3]
Hematocrit (in%) 40 (27–53) 40 (29–50)
White Cell Count (in 61000 per microlitre) 7.2 (2.3–24.2) 6.7 (3.0–20.0)
Platelet Count (in 61000 per microlitre) 192 (66–546) 180 (65–380)
* ALT ( in U/L ) 30(11–240) 37 (12–200)
**AST ( in U/L ) 43 (20–354) 52 (21–169)
Total Bilirubin ( in mg/dL ) 0.8 (0.17–3.6) 0.89 (0.18–3.2)
Baseline epidemiological, clinical and laboratory features at presentation of all intention to treat patients showing a comparison between culture positive and culture
negative groups.
*ALT (serum alanine aminotransferase) normal range 5–34 U/L
**AST (serum aspartate aminotransferase) normal range 5–34 U/L
All data presented as median (range) unless specified.
doi:10.1371/journal.pone.0000542.t001
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PLoS ONE | www.plosone.org 5 June 2007 | Issue 6 | e542enterica serotype Typhi or Paratyphi A are the two most commonly
isolated pathogens from the blood in febrile patients in our hospital
[15]. Before the advent of multi-drug-resistant (MDR) S. Typhi,
chloramphenicol, ampicillin or cotrimoxazole were successfully
used as the first line drug in the treatment of enteric fever. After
the emergence of MDR strains, fluoroquinolones and third-
generation cephalosporins have been suggested and used as
alternative antimicrobials [16,13]. However the emergence and
spread of point mutations in the gyrA gene of the bacterial genome
[17] has conferred resistance to nalidixic acid and reduced
susceptibility to the commonly used fluoroquinolones such as
ofloxacin, leading to a poorer clinical response [18,19]. A recent
study in Viet Nam (CM Parry, unpublished) showed ofloxacin at
the dose of 20 mg/kg/day was able to achieve a cure rate in only
Table 2. Baseline characteristics at presentation of culture positive patients.
..................................................................................................................................................
PATIENT CHARACTERISTICS GATIFLOXACIN (n=92) CEFIXIME (n=77)
No of males/No of females 67/25 44/33
Age (yrs) 18 (2.75–45) 15 (3–50)
Number Aged ,14 years (%) 27 (29%) 33 (43%)
Weight (Kg) 49 (10–70) 42 (11–73)
Duration of fever before treatment (days) 5.2 5.4
Median oral temperature at presentation(95% CI, range) (in degrees C) 39 (38.9–39.2; 37.5–41.0) 39 (38.8–39.2; 36.8–40.5)
Headache, Number with (%) (median duration [days]) 88 (95.7%) (5) 76 (98.7%) (4.5)
Anorexia, Number with (%) (median duration [days]) 73 (79.3%) (4) 56 (73%) (4)
Abdominal Pain, Number with (%) (median duration [days]) 43 (46.7%) (4) 40 (52%) (4)
Cough, Number with (%) (median duration [days]) 37 (40.2%) (3) 22 (29%) (3)
Diarrhoea, Number with (%) (median duration [days]) 21 (22.8%) (3) 20 (26%) (3)
Vomiting, Number with (%) (median duration [days]) 17 (18.5%) (2) 10 (13%) (1.5)
Abdominal tenderness ( n [%]) ) 14 (15.2%) 8 (10.4%)
Splenomegaly ( n [%]) 10 (10.9%) 8 (10.4%)
Hepatomegaly ( n [%]) 5 (5.4%) 4 (5%)
Hematocrit (in%) 41 (30–50) 40 (29–50)
White Cell Count (in 61000 per microlitre) 6.8(3.0–18) 6.7 (3.1–20)
Platelet Count (in 61000 per microlitre) 180(65–367) 186 (120–380)
* ALT ( in U/L ) 36 (12–180) 39(18–200)
**AST ( in U/L ) 53 (24–155) 49 (21–169)
Total Bilirubin ( in mg/dL ) 0.85 (0.18–3.2) 0.9 (0.35–2.3)
Positive pretreatment fecal cultures ( n [%]) 9 (9.8%) 3 (3.8%)
Baseline epidemiological, clinical and laboratory features at presentation of all blood culture positive patients showing a comparison between the gatifloxacin and
cefixime arms.
*ALT (serum alanine aminotransferase) normal range 5–34 U/L
**AST (serum aspartate aminotransferase) normal range 5–34 U/L
All data presented as median ( range) unless specified.
doi:10.1371/journal.pone.0000542.t002
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Figure 2. Proportion of all patients still febrile. Kaplan-Meier survival
curve showing the proportion of all patients(ITT) still febrile through
time.
doi:10.1371/journal.pone.0000542.g002
Figure 3. Proportion of culture positive patients still febrile. Kaplan-
Meier survival curve showing the proportion of culture positive(PP)
patients still febrile through time.
doi:10.1371/journal.pone.0000542.g003
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gatifloxacin is the most effective and appropriate choice for
treatment of enteric fever. Gatifloxacin (Sandoz, India) is relatively
inexpensive (US$1.2 for a 7 day treatment course) and needs to be
administered just once a day; both of these features are attractive
in this setting. Gatifloxacin has a different binding motif than some
other fluroquinolones[20], and this characteristic enables it to
retain activity against Salmonella enterica serovar Typhi or Salmonella
enterica serovar Paratyphi A even in the presence of marked
reduction in sensitivity to the older fluoroquinolones [17].
Cefixime, a third generation cephalosporin, is widely trusted to
be effective for enteric fever as first line treatment, and is also used
as second line therapy when initial treatment with a fluoroquino-
lone in a patient suspected to be enteric fever fails [13]. The fact
that we saw a high overall failure rate associated with cefixime
despite all of the strains being fully sensitive in vitro to the drug
shows that the mechanism of action of cefixime [21,22] may not
be suited to the eradication of S. Typhi or Paratyphi A from the
body or blood, and the poor intracellular penetration into
macrophages and reticulo endothelial tissues where the typhoid
organisms colonize [16] may be the cause of high failure rates.
This study was unique in that we used CMAs to simulate
a hospital setup in the community. CMA’s directly observed
patients taking the therapies, monitored fever and identified
complications early; these characteristics have not been used in the
past for typhoid trials although enteric fever in endemic areas [1] is
treated on an outpatient basis. A major advantage of follow-up
using CMAs was that the health workers knew the exact house
location of the patients, and therefore follow up even after the
successful completion of the initial seven-day drug trial was
possible. In developing countries follow up of patients can be very
difficult because of a lack of a proper address and relative
unavailability of other means of communication, for example,a
telephone.
In addition to its relevance to culture confirmed enteric fever,
another major strength of this large randomized study is that
gatifloxacin proved to be more efficacious than cefixime with
respect to fever clearance time and failure rates, even in the
subgroup of patients who were clinically presumed to have enteric
fever but who had a negative blood culture. Antibiotic treatment
for typhoid in highly endemic areas is usually started based on the
presence of a ‘‘syndromic’’ illness (acute fever for a few days and
constitutional symptoms with no known source of infection) before
culture results are known. Enteric fever, which continues to be
a neglected disease [23], is an important cause of morbidity and
mortality, and facilities for blood culture or other reliable methods
of diagnosis rarely exist in this setting.
Generalizability
Despite widespread resistance to Nalidixic acid in Kathmandu,
and rising MICs to the older fluoroquinolones, ciprofloxacin and
ofloxacin, gatifloxacin has proven to be a potent drug for the
treatment of enteric fever. Our study has relevance to South Asia,
as resistance to nalidixic acid is widely prevalent there. Inevitably
there will be emergence of resistance to gatifloxacin in areas with
both MDR and NARST; and in this situation alternative
antibiotics like azithromycin may need to be used. Of interest, in
keeping with anecdotal reports from elsewhere in South Asia, only
one strain was resistant to chloramphenicol in the present study. In
areas of the world where chloramphenicol susceptibility has
reemerged there may be an argument for reassessing chloram-
phenicol.
In the present study Gatifloxacin was associated with nausea in
12% of patients and it may be important to forewarn patients of
this possible side effect. There have been sporadic reports of
dysglycemia caused by gatifloxacin [24–26], and a recent
population-based, case controlled study examining gatifloxacin
usage amongst elderly individuals in Canada (mean age 77 years)
who developed dysglycemia [27] also raises possible concerns. We
did not do any blood sugar testing to look for dysglycemia.
However in a study involving a younger age group where blood
sugar testing was done the results revealed no dysglycemia: 887
children were treated with gatifloxacin (10 mg/kg) for otitis media
and were followed for a year with no signs of alteration of glucose
homeostasis either acutely or otherwise [28]. Clearly, it would be
prudent to treat diabetics and elderly people suffering from enteric
fever with an alternative antibiotic such as azithromycin and avoid
the potential problems in this specific population with gatifloxacin.
Limitations of the study The DSMC advised the Principal
Investigators in this study to stop recruitment to the trial based on
a priori defined difference (p,0.01) between the two treatment
arms in the primary endpoints of the study. It is possible that if the
trial had been continued with a larger sample size, other important
information could have been gathered. In addition if patients and/
or investigators had been blinded to treatment assignments, the
Figure 4. Proportion of relapse free patients. Kaplan-Meier survival
curve showing the proportion of relapse free patients in the culture
positive population.
doi:10.1371/journal.pone.0000542.g004
Figure 5. Proportion of overall failure free patients. Kaplan-Meier
survival curve showing the proportion of overall failure free patients in
the culture positive population.
doi:10.1371/journal.pone.0000542.g005
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typhoid trials, it was not possible to do this due to the difference in
dosing schedule for the two drugs being compared. Another
limitation of this study was that temperature was only measured
every 12 hours. However, to address this limitation, and to avoid
missing increases in temperature, we checked temperatures for
10 days after enrollment, or for 48 hours after resolution of fever,
whichever came later, in all patients. Finally, a telephone or
internet based system of randomization would be ideal, but such
a system does not exist here.
Overall evidence
We have compared the outcomes from our trial with those of other
comparable studies, identified from a recent Cochrane review [4],
WHO typhoid guidelines [10], and a search of Medline using
these terms: cefixime, typhoid trials. The findings in our study are
consistent with those of a 1995 study done in Viet Nam which
showed that cefixime (20 mg/kg/day) for 7 days was inferior to
ofloxacin (10 mg/kg/day) for 5 days in the treatment of MDR
typhoid fever in children[14]. However other studies have
suggested cefixime can be successful in the treatment of enteric
fever [29–33]. Overall these studies, both descriptive and
randomized, have examining the use of cefixime in confirmed
enteric fever (total of 292 patients) and with treatment durations of
mostly 14 days, have found failure rates ranging from 4% to 23%.
Besides the general undesirability of a longer course with cefixime
with increased morbidity and possibly complications, this drug is
also more expensive (a 7-day course costs US $7 (Blue Cross
Laboratories, India)). The present study is the largest randomized
controlled trial ever conducted with cefixime in enteric fever and
clearly shows, even in a setting with fully sensitive strains, that
cefixime is a poor drug for this disease. These findings are contrary
to the recommendation by many sources[13,1] including the
World Health Organization[10] that cefixime can be used as first
or second line therapy in the treatment of enteric fever. Based on
the present study, we believe gatifloxacin to be an optimal choice
in the treatment of uncomplicated enteric fever.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0000542.s001 (0.05 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0000542.s002 (0.05 MB
DOC)
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